Physician profile
Sunil Nath
NPI 1811984776
$12,902.41
in general payments reported to CMS, 2019-2025
34 companies · $736 in 2025
The $736 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,232 · 2020: $1,246 · 2021: $591 · 2022: $1,177 · 2023: $1,641 · 2024: $1,281 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,656.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,445.78 | 2019-2025 | Ensite Precision, Jot Dx, Aveir |
| Boston Scientific Corporation | $3,181.54 | 2019-2025 | Watchman Access System, General - Therapies |
| Medtronic Vascular, INC. | $3,113.93 | 2019-2020 | |
| Amgen INC. | $520.81 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $362.04 | 2023-2025 | Inspiris Resilia Aortic Valve, Evoque, Pascal |
| E.R. Squibb & Sons, L.L.C. | $338.05 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $307.34 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $242.13 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $217.79 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $114.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.36 | 2019-2024 | Jardiance |
| Scpharmaceuticals INC. | $94.96 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $83.50 | 2024-2025 | Optimizer |
| Medtronic, INC. | $82.98 | 2021-2024 | Concertotm |
| Janssen Pharmaceuticals, INC | $78.19 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $77.01 | 2024-2025 | Verquvo |
| Heartflow, INC. | $63.95 | 2023-2024 | Ffrct |
| Inspire Medical Systems, INC. | $52.07 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $46.68 | 2022 | |
| Astellas Pharma US INC | $43.27 | 2019 | |
| Cvrx, INC. | $41.08 | 2024 | Barostim Neo System |
| Novo Nordisk INC | $39.20 | 2024 | Rybelsus, Ozempic |
| Kestra Medical Technology Services, INC. | $33.65 | 2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals Lp | $31.95 | 2019-2025 | Farxiga |
| Chiesi USA, INC. | $27.75 | 2019-2022 | |
| Cardiovascular Systems INC. | $25.27 | 2019 | |
| Stryker Corporation | $20.85 | 2024 | Target |
| Kiniksa Pharmaceuticals International, Plc | $19.34 | 2024 | Arcalyst |
| Cleerly, INC. | $19.21 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Ethicon US, LLC | $14.65 | 2025 | Ethicon, Dermabond Prineo, Stratafix |
| Lundbeck LLC | $14.23 | 2019 | |
| Cardiva Medical, INC. | $13.42 | 2022 | |
| Portola Pharmaceuticals, LLC | $13.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Nath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.